(NASDAQ: UBX) Unity Biotechnology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.81%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.63%.
Unity Biotechnology's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast UBX's revenue for 2026 to be $449,663,031, with the lowest UBX revenue forecast at $449,663,031, and the highest UBX revenue forecast at $449,663,031. On average, 1 Wall Street analysts forecast UBX's revenue for 2027 to be $945,657,023, with the lowest UBX revenue forecast at $945,657,023, and the highest UBX revenue forecast at $945,657,023.
In 2028, UBX is forecast to generate $1,429,857,679 in revenue, with the lowest revenue forecast at $1,429,857,679 and the highest revenue forecast at $1,429,857,679.